Anti-Cardiac Troponin I (phospho S22 + S23) antibody (ab58545)

Overview

  • Product name
    Anti-Cardiac Troponin I (phospho S22 + S23) antibody
    See all Cardiac Troponin I primary antibodies
  • Description
    Rabbit polyclonal to Cardiac Troponin I (phospho S22 + S23)
  • Specificity
    Detects endogenous levels of cardiac Troponin I only when phosphorylated at serine 22/serine 23
  • Tested applications
    Suitable for: WB, ELISAmore details
  • Species reactivity
    Reacts with: Mouse, Human
    Predicted to work with: Rat
  • Immunogen

    Synthetic phosphopeptide derived from mouse TNNI3 around the phosphorylation site of serine 22 and serine 23 (RRSPSPA)

  • Positive control
    • Mouse heart cell extract

Properties

Applications

Our Abpromise guarantee covers the use of ab58545 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Detects a band of approximately 30 kDa (predicted molecular weight: 24 kDa).
ELISA 1/20000.

Target

  • Function
    Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
  • Involvement in disease
    Defects in TNNI3 are the cause of cardiomyopathy familial hypertrophic type 7 (CMH7) [MIM:613690]. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
    Defects in TNNI3 are the cause of cardiomyopathy familial restrictive type 1 (RCM1) [MIM:115210]. RCM1 is an heart muscle disorder characterized by impaired filling of the ventricles with reduced diastolic volume, in the presence of normal or near normal wall thickness and systolic function.
    Defects in TNNI3 are the cause of cardiomyopathy dilated type 2A (CMD2A) [MIM:611880]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
    Defects in TNNI3 are the cause of cardiomyopathy dilated type 1FF (CMD1FF) [MIM:613286]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
  • Sequence similarities
    Belongs to the troponin I family.
  • Information by UniProt
  • Database links
  • Alternative names
    • cardiac muscle antibody
    • Cardiac troponin I antibody
    • cardiomyopathy, dilated 2A (autosomal recessive) antibody
    • Cardiomyopathy, familial hypertrophic, 7, included antibody
    • CMD1FF antibody
    • CMD2A antibody
    • CMH7 antibody
    • cTnI antibody
    • Familial hypertrophic cardiomyopathy 7 antibody
    • MGC116817 antibody
    • RCM1 antibody
    • Tn1 antibody
    • Tni antibody
    • TNN I3 antibody
    • TNNC 1 antibody
    • TNNC1 antibody
    • TNNI3 antibody
    • TNNI3_HUMAN antibody
    • Troponin I antibody
    • Troponin I cardiac antibody
    • Troponin I cardiac muscle antibody
    • Troponin I cardiac muscle isoform antibody
    • Troponin I type 3 cardiac antibody
    • troponin I, cardiac 3 antibody
    • TroponinI antibody
    • Ttroponin I type 3 (cardiac) antibody
    see all

Images

  • All lanes : Anti-Cardiac Troponin I (phospho S22 + S23) antibody (ab58545) at 1/500 dilution

    Lane 1 : Mouse heart cell extract
    Lane 2 : Mouse heart cell extract with peptide


    Predicted band size : 24 kDa
    Observed band size : 30 kDa (why is the actual band size different from the predicted?)

References

This product has been referenced in:
  • Surdo NC  et al. FRET biosensor uncovers cAMP nano-domains at ß-adrenergic targets that dictate precise tuning of cardiac contractility. Nat Commun 8:15031 (2017). WB . Read more (PubMed: 28425435) »
  • Mera C  et al. Mechanisms of favorable effects of Rho kinase inhibition on myocardial remodeling and systolic function after experimental myocardial infarction in the rat. Ther Adv Cardiovasc Dis 10:4-20 (2016). Read more (PubMed: 26490279) »

See all 4 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab58545.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up